52 Week Range
As of on the Shanghai Stock Exchange ∙ Minimum 15 minute delay
3M AVG Volume
52 Week High
52 Week Low
Shares Out (MIL)
Market Cap (MIL)
Dividend (Yield %)
Bio-Thera Solutions' Prelim 2019 Net Loss Of 1.0 Bln Yuan
Bio-Thera Solutions' Trading Of Shares To Debut On Feb 21 In Shanghai Star Market
Bio-Thera Solutions' Shanghai IPO 3,224.91 Times Oversubscribed
Bio-Thera Solutions, Ltd. is a China-based company mainly engaged in the research and development of innovative drugs and biosimilars. The Company is committed to the development of a new generation of antibody drugs to treat cancer, autoimmune diseases, cardiovascular diseases and other major diseases that endanger human life and health. The Company's main products include adalimumab BAT1406, bevacizumab BAT1706, BAT8001, tocilizumab BAT1806, batifaban BAT2094, BAT8003 and so on.
Price To Earnings (TTM)
Price To Sales (TTM)
Price To Book (MRQ)
Price To Cash Flow (TTM)
Total Debt To Equity (MRQ)
LT Debt To Equity (MRQ)
Return on Investment (TTM)
Return on Equity (TTM)
China has approved the use of Swiss drugmaker Roche's <ROG.S> anti-inflammation drug Actemra for patients who develop severe complications from the coronavirus as it urgently hunts for new ways to combat the deadly infection that is spreading worldwide.
China will use a Roche Holding AG arthritis drug to treat some coronavirus patients in severe conditions, health authorities said on Wednesday, as the country seeks to build up treatment regimens to help the infected recover.
* SAYS PRELIM 2019 NET LOSS OF 1.0 BILLION YUAN ($142.60 million) VERSUS NET LOSS OF 553.1 MILLION YUAN YEAR EARLIER Source text in Chinese: https://bit.ly/3cb5BOo Further company coverage: ($1 = 7.0128 Chinese yuan renminbi) (Reporting by Hong Kong newsroom)
* SAYS TRADING OF SHARES TO DEBUT ON FEB 21 IN SHANGHAI STAR MARKET Source text in Chinese: http://static.sse.com.cn/disclosure/listedinfo/bulletin/star/c/688177_20200220_1.pdf (Reporting by Hong Kong newsroom)
* SAYS ITS INITIAL SHANGHAI SHARE OFFERING 3,224.91 TIMES OVERSUBSCRIBED Source text in Chinese: https://bit.ly/3bspIqJ Further company coverage: (Reporting by Hong Kong newsroom)
* SAYS IT AIMS TO RAISE UP TO 2.0 BILLION YUAN ($285.70 million) IN INITIAL SHANGHAI SHARE OFFERING Source text in Chinese: https://bit.ly/2OFu6sZ Further company coverage: ($1 = 7.0003 Chinese yuan renminbi) (Reporting by Hong Kong newsroom)
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.